2. Search Result
Search Result
Results for "

CDK4/9-IN-1

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
製品番号 製品名 Target 研究分野 構造式
  • HY-148065
    FMF-06-098-1

    		PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .
    FMF-06-098-1
  • HY-16559
    Riviciclib hydrochloride
    3 Publications Verification

    P276-00

    		 CDK Apoptosis Cancer
    Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .
    Riviciclib hydrochloride
  • HY-178452
    PROTAC CDK4/6/9 degrader 1

    		PROTACs CDK Apoptosis Cancer
    PROTAC CDK4/6/9 degrader 1 is a CDK4/6/9 PROTAC degrader. PROTAC CDK4/6/9 degrader 1 degrades CDK4, CDK6, and CDK9 in TNBC cells and inhibits TNBC cell proliferation. PROTAC CDK4/6/9 degrader 1 induces G1 phase arrest, promotes apoptosis, and suppresses cell migration and invasion in TNBC cells. PROTAC CDK4/6/9 degrader 1 can be used for the study of triple-negative breast cancer (TNBC). (Pink: CDK4/6/9 ligand (HY-168440), Blue: CRBN Ligand (HY-14658), Black: Linker (HY-178512), E3 ligase ligand-linker conjugate (HY-178515)) .
    PROTAC CDK4/6/9 degrader 1
  • HY-16559A
    Riviciclib

    P276-00 free base

    		 CDK Cancer
    Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .
    Riviciclib
  • HY-170815
    CDK4/9-IN-1

    		CDK Cancer
    CDK4/9-IN-1 (Compound 29) is a selective dual CDK4/9 inhibitor with IC50 values of 23 nM and 12 nM, respectively. CDK4/9-IN-1 is promising for research of cancers .
    CDK4/9-IN-1
  • HY-178512
    Piperazine-CO-C1-Azacyclohexane-C1-Piperazine

    		PROTAC Linkers Cancer
    Piperazine-CO-C1-Azacyclohexane-C1-Piperazine is a PROTAC linker can be used in the synthesis of PROTACs, such as PROTAC CDK4/6/9 degrader 1 (HY-178452) .
    Piperazine-CO-C1-Azacyclohexane-C1-Piperazine
  • HY-153221
    QR-6401

    		CDK Cancer
    QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC50 values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3 and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .
    QR-6401
  • HY-178515
    Thalidomide-piperazine-CO-C-azacyclohexane-C1-piperazine

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Thalidomide-piperazine-CO-C-azacyclohexane-C1-piperazine is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-piperazine-CO-C-azacyclohexane-C1-piperazine can be used for synthesizing PROTAC CDK4/6/9 degrader 1 (HY-178452) .
    Thalidomide-piperazine-CO-C-azacyclohexane-C1-piperazine

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: